New paths to pain relief: a better understanding of the mechanisms by which pain signals are relayed in the nervous system is paving the way for novel treatments

Article Abstract:

A new generation of painkillers is being developed. Such drugs do not have the adverse side effects of those currently available for use with patients with headache, back pain, and also the extreme pain associated with cancer.

Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, Analgesics, Antipyretics, Bulk drugs

---

Genentech enlightens other angiogenesis programs

Article Abstract:

South San Francisco, CA-based Genentech announced recently that its phase II trial of recombinant vascular endothelial growth factor (rhVEGF-165) protein did not meet its primary goal which was the improvement of exercise tolerance 60 days after drug administration in coronary artery disease. The results reveal that protein therapy, especially by intravenous delivery, may be less effective than gene therapy in fostering angiogenesis; but the news does not negate other research programs.

Comment:

South San Francisco, CA-based Genentech announced recently that its phase II trial of recombinant vascular endothelial growth factor (rhVEGF-165) protein did not meet its primary goal which was the improvement of exercise tolerance 60 days after drug administration in coronary artery disease.

Biological Product (except Diagnostic) Manufacturing, Recombinant DNA Products, Cardiovascular Preparations, Recombinant DNA, Genentech Inc., Cardiovascular agents

---

Tumor angiogenesis-new drugs on the block: angeogenisis inhibitors could represent adjunct to traditional cancer treatments, but the most effective routes for therapeutic intervention remain unclear

Article Abstract:

Angeogenesis inhibitors, therapies that inhibit the growth of blood vessels to support tumors, offer significant promise as anticancer agents. Such therapies have attacked tumors which have been resistant to conventional chemotherapy. There are at least 27 angiogenic drugs now being researched by drug companies.

Anticancer Drugs, Antineoplastic agents

Similar abstracts:

• Abstracts: Growth stocks are out of fashion but watch for the swing back. Going with the flow
• Abstracts: New proposed code sec. 367(b) regulations govern the carryout of tax attributes in reorganizations involving foreign corporations
• Abstracts: The growing muddle regarding basis for shareholder notes in tax-free exchanges. Supreme Court grants certiorari in Gitlitz
• Abstracts: On-site photofinishing services versus Internet opportunities. Online pro services vs traditional photo labs
• Abstracts: In good company: With an evergrowing number of corporate websites to choose from, we offer guidance on how to sort the wheat from the chaff

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.